JNJ acquired these shares as part of the now-defunct HCV collaboration announced in 2015 (#msg-113830307) at a price of $12.25, almost 4x the current (AH) price.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”